Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 25.9% in December

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 17,701 shares, a growth of 25.9% from the November 30th total of 14,057 shares. Approximately 1.3% of the shares of the stock are sold short. Based on an average daily volume of 39,649 shares, the short-interest ratio is presently 0.4 days. Based on an average daily volume of 39,649 shares, the short-interest ratio is presently 0.4 days. Approximately 1.3% of the shares of the stock are sold short.

Indaptus Therapeutics Price Performance

INDP stock opened at $2.91 on Friday. The firm has a market capitalization of $5.09 million, a P/E ratio of -0.09 and a beta of 0.98. Indaptus Therapeutics has a 52-week low of $1.65 and a 52-week high of $47.60. The company’s 50 day simple moving average is $2.53 and its 200-day simple moving average is $5.44.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($2.98) EPS for the quarter, topping analysts’ consensus estimates of ($4.17) by $1.19. Sell-side analysts predict that Indaptus Therapeutics will post -1.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

INDP has been the subject of a number of research reports. Wall Street Zen cut shares of Indaptus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Indaptus Therapeutics presently has an average rating of “Sell”.

Institutional Investors Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics as of its most recent SEC filing. Institutional investors own 7.06% of the company’s stock.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.